| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
13.00(B) |
| Last
Volume: |
505,301 |
Avg
Vol: |
422,610 |
| 52
Week Range: |
$210.76 - $276.73 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
532,980 |
641,880 |
704,763 |
1,849,369 |
| Total Sell Value |
$131,193,525 |
$156,567,388 |
$170,874,254 |
$455,640,758 |
| Total People Sold |
8 |
8 |
8 |
10 |
| Total Sell Transactions |
70 |
86 |
98 |
264 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Benkowitz Michael |
President and COO |
• • – |
2021-12-16 |
4 |
OE |
$61.06 |
$244,240 |
D/D |
4,000 |
6,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-12-14 |
4 |
D |
$193.93 |
$775,720 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-12-14 |
4 |
OE |
$61.06 |
$244,240 |
D/D |
4,000 |
6,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-12-07 |
4 |
D |
$190.41 |
$761,640 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-12-07 |
4 |
OE |
$61.06 |
$244,240 |
D/D |
4,000 |
6,235 |
|
- |
|
| Olian Judy D. |
Director |
– • – |
2021-11-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
920 |
8,230 |
|
- |
|
| Benkowitz Michael |
President and COO |
• – – |
2021-11-23 |
4 |
D |
$201.58 |
$806,320 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• – – |
2021-11-23 |
4 |
OE |
$61.06 |
$244,240 |
D/D |
4,000 |
6,235 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2021-11-22 |
4 |
AS |
$200.42 |
$617,895 |
D/D |
(3,083) |
130 |
|
-7% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2021-11-22 |
4 |
OE |
$53.42 |
$164,694 |
D/D |
3,083 |
3,213 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-11-18 |
4 |
D |
$202.61 |
$810,440 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-11-18 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-11-18 |
4 |
D |
$197.78 |
$1,195,957 |
D/D |
(6,000) |
36,369 |
|
- |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-11-18 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,369 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2021-11-17 |
4 |
AS |
$201.90 |
$622,458 |
D/D |
(3,083) |
130 |
|
-10% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2021-11-17 |
4 |
OE |
$53.42 |
$164,694 |
D/D |
3,083 |
3,213 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-11-16 |
4 |
D |
$203.24 |
$812,960 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-11-16 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Rothblatt Martine A |
Chairman & CEO |
• • – |
2021-11-15 |
4 |
AS |
$203.45 |
$627,236 |
D/D |
(3,083) |
130 |
|
-13% |
|
| Rothblatt Martine A |
Chairman & CEO |
• • – |
2021-11-15 |
4 |
OE |
$53.42 |
$164,694 |
D/D |
3,083 |
3,213 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-11-11 |
4 |
D |
$200.90 |
$803,600 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-11-11 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Patusky Christopher |
Director |
• • – |
2021-11-11 |
4 |
D |
$200.90 |
$401,800 |
D/D |
(2,000) |
1,680 |
|
- |
|
| Patusky Christopher |
Director |
• • – |
2021-11-11 |
4 |
OE |
$63.90 |
$127,800 |
D/D |
2,000 |
3,680 |
|
- |
|
| Rothblatt Martine A |
Chairman & CEO |
• • – |
2021-11-10 |
4 |
AS |
$200.00 |
$616,600 |
D/D |
(3,083) |
130 |
|
-12% |
|
5072 Records found
|
|
Page 29 of 203 |
|
|
1.40 (0.51%) 
